Prime Medicine, Inc.PRMEEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-68.0M
Net Profit
$-65.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.72
Prime Medicine, Inc. Q4 FY2023 Financial Summary
Prime Medicine, Inc. reported revenue of $0 for Q4 FY2023, with a net profit of $-65.6M (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-65.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2023 |
Prime Medicine, Inc. Annual Revenue by Year
Prime Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.6M |
| 2023 | $0 |
Prime Medicine, Inc. Quarterly Revenue & Net Profit History
Prime Medicine, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $838.0K | -61.6% | $-46.1M | -5498.7% |
| Q3 FY2025 | $1.2M | +486.1% | $-50.6M | -4129.1% |
| Q2 FY2025 | $1.1M | — | $-52.6M | -4716.7% |
| Q1 FY2025 | $1.5M | +146.0% | $-51.9M | -3568.8% |
| Q4 FY2024 | $2.2M | — | $-42.3M | -1936.6% |
| Q2 FY2024 | $0 | — | $-55.3M | N/A |
| Q1 FY2024 | $591.0K | — | $-45.8M | -7743.0% |
| Q4 FY2023 | $0 | — | $-65.6M | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $591000 | $0 | $2.2M | $1.5M | $1.1M | $1.2M | $838000 |
| YoY Growth | N/A | N/A | N/A | N/A | 146.0% | N/A | 486.1% | -61.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $193.9M | $311.4M | $259.7M | $297.5M | $328.2M | $279.0M | $385.0M | $342.7M |
| Liabilities | $60.8M | $67.6M | $63.1M | $144.4M | $221.2M | $218.1M | $223.2M | $221.9M |
| Equity | $133.1M | $243.8M | $196.6M | $153.1M | $106.9M | $60.9M | $161.8M | $120.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-43.9M | $-67.7M | $-45.5M | $16.2M | $-48.9M | $-41.4M | $-35.0M | $-37.3M |